SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cell therapy takes on hard-to-treat brain cancer
Disease control Recruiting nowThis early-phase study tests a new cell therapy called MB-CART19.1 for people with central nervous system lymphoma that has returned or not responded to other treatments. The therapy uses a patient's own immune cells, modified to attack the cancer, and is made on-site. The main g…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
Promising combo tackles tough brain cancer in small trial
Disease control Recruiting nowThis study tests a two-drug combination (zanubrutinib and pemetrexed) followed by a maintenance drug for people whose central nervous system lymphoma has returned or stopped responding to treatment. About 15 adults with this rare brain lymphoma will receive the drugs to see if tu…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New drug may stop aggressive lymphoma relapse after transplant or CAR-T
Disease control Recruiting nowThis study tests whether a daily pill called acalabrutinib can help prevent relapse in people with very high-risk large B-cell lymphoma after they have received a stem cell transplant or CAR-T cell therapy. The drug works by blocking a protein that helps cancer cells grow. The tr…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC
-
New drug combo shows promise for brain cancer in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called glofitamab, given after a pre-treatment with obinutuzumab, for people with central nervous system (CNS) lymphoma—a rare cancer in the brain or spinal cord. The study aims to see if the combination is safe and tolerable, and how well …
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 08, 2026 13:17 UTC
-
New drug cocktail targets Hard-to-Treat brain lymphoma
Disease control Recruiting nowThis early-phase study tests whether combining two drugs, epcoritamab and ibrutinib, is safe for people whose central nervous system lymphoma has come back or not responded to treatment. About 26 adults with this rare cancer will receive the drug combination. The main goal is to …
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 03, 2026 12:06 UTC
-
Blood cancer Patients' brain power under microscope in new study
Knowledge-focused Recruiting nowThis study tracks memory and thinking changes in 100 adults with blood cancers who receive whole brain radiation. Researchers will test cognitive skills like recall and attention over time. The goal is to better understand the mental side effects of this treatment, not to change …
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:05 UTC